PHI enters the US capital market - shares now also traded on OTCQB
Rhea-AI Summary
Phase Holographic Imaging (PHI) announced its listing on the OTCQB Venture Market in the U.S., effective August 15, 2024, under the symbol PHIXF. This move is aimed at improving accessibility and engagement with U.S. investors, leveraging existing reporting standards to meet U.S. requirements. The listing signifies PHI’s growth and commitment to the U.S. market, enhancing trading transparency and liquidity.
Positive
- PHI's listing on the OTCQB Venture Market increases accessibility for U.S. investors.
- Trading on the OTCQB is expected to enhance liquidity and visibility.
- PHI met financial standards and corporate governance to qualify for OTCQB listing.
Negative
- None.
Effective August 15th, PHI has been admitted to trading on the OTCQB under the symbol "PHIXF". OTC Markets Group operates regulated markets for trading
PHI, already listed on the Spotlight Stock Market, can use its existing reporting standards to meet
PHI's CEO, Patrik Eschricht, comments:
"We are excited to expand our market presence by listing on the OTCQB. This new platform offers our investors greater accessibility and visibility in the U.S. market, aligning with our mission to advance regenerative medicine. This dual listing is expected to enhance liquidity, provide greater value to our shareholders, and support the continued growth of PHI."
For more information contact:
Lisa Bodily, Head of IR, ir@phiab.com, +46 73 026 87 87
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in
Photo: https://mma.prnewswire.com/media/2483603/PHI_AB_OTCQB.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/phi-enters-the-us-capital-market--shares-now-also-traded-on-otcqb-302224242.html
SOURCE Phase Holographic Imaging PHI AB